Donald Tusk
EMA’s PRIME scheme launches three major new features
The scheme supports the development of treatments targeting unmet medical needs in the EU
BMS’ Opdivo gets expanded FDA and EU approval for Hodgkin lymphoma
This type of cancer is the most common one diagnosed in teenagers
Lilly announces plan for new $3bn facility to boost manufacturing in Europe
The facility will be built in the Netherlands and will increase capacity for the company's oral medicines portfolio
EU medicine shortages hit record highs in 2023 and 2024
Even with countermeasures in place, European auditors warn that the risks remain elevated
ISPOR hosts expert webinar exploring the value of ECAs for regulatory and HTA evidence needs
On Tuesday, October 7th, you are invited to join a Genesis Research Group-led webinar exploring the value of External Control Arm (ECA) studies. Gaining traction as part of evidence generation...
EatMoreFruit Selected by European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) to Lead Strategic PR and Communications for European Laboratory Day
The European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) has selected London-based healthcare specialist EatMoreFruit to raise awareness and engagement around its ‘EU Lab Day’; an event co-ordinating 42...
EU establishes €100m funding scheme for projects tackling public health threats
The HERA Invest fund will focus on health emergency prevention and preparedness initiatives
AZ’s Saphnelo receives EU approval for systemic lupus erythematosus
There are an estimated 250,000 people living with SLE in Europe and this is the first new drug to gain EU approval in over ten years
EMA establishes DARWIN EU Coordination Centre
The new centre will give the EMA and other EU member states access to reliable, real-world evidence for EU medicine assessments
Future of MHRA uncertain amid Brexit-fuelled shake up
Trade unions and regulatory experts warn that budget and staff cuts may lead to drug approval delays or the UK regulator simply rubber-stamping EMA decisions
MHRA outlines two-year delivery plan with ‘patient first’ focus
New delivery plan also outlines strategy for UK regulatory body following Brexit